Checkpoint Therapeutics (NASDAQ:CKPT) Now Covered by D. Boral Capital

D. Boral Capital initiated coverage on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research note issued to investors on Monday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $9.00 target price on the stock.

CKPT has been the topic of a number of other reports. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Checkpoint Therapeutics in a research note on Monday, December 16th. Lake Street Capital increased their target price on Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 16th.

Checkpoint Therapeutics Trading Up 5.0 %

Checkpoint Therapeutics stock opened at $3.33 on Monday. The business’s 50 day simple moving average is $3.63 and its 200 day simple moving average is $2.89. Checkpoint Therapeutics has a 12 month low of $1.38 and a 12 month high of $4.50. The company has a market cap of $162.61 million, a price-to-earnings ratio of -1.81 and a beta of 1.36.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.08). As a group, equities research analysts forecast that Checkpoint Therapeutics will post -0.91 earnings per share for the current fiscal year.

Insider Transactions at Checkpoint Therapeutics

In related news, CEO James F. Oliviero III sold 220,230 shares of the stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $3.38, for a total value of $744,377.40. Following the sale, the chief executive officer now owns 3,194,583 shares in the company, valued at approximately $10,797,690.54. This trade represents a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO William Garrett Gray sold 268,432 shares of the business’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $4.01, for a total value of $1,076,412.32. Following the transaction, the chief financial officer now owns 1,032,754 shares of the company’s stock, valued at approximately $4,141,343.54. The trade was a 20.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On Checkpoint Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CKPT. Virtu Financial LLC purchased a new position in Checkpoint Therapeutics in the 3rd quarter worth approximately $30,000. XTX Topco Ltd purchased a new position in Checkpoint Therapeutics in the second quarter worth $34,000. Gladstone Institutional Advisory LLC increased its stake in Checkpoint Therapeutics by 141.4% in the third quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock valued at $78,000 after acquiring an additional 20,500 shares during the last quarter. Magnus Financial Group LLC increased its stake in Checkpoint Therapeutics by 12.9% in the third quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after acquiring an additional 4,000 shares during the last quarter. Finally, Choreo LLC raised its position in Checkpoint Therapeutics by 12.2% during the second quarter. Choreo LLC now owns 65,002 shares of the company’s stock valued at $133,000 after purchasing an additional 7,080 shares in the last quarter. 22.00% of the stock is owned by hedge funds and other institutional investors.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.